Mc Cormack Lab Publications 2012-23

PUBLICATIONS McCormack 2012 – 2022

  1. Eriksen-Gjerstad M, Tveit Karlsen I, Fandalyuk Z, Benjaminsen S, Baran-Marszak F, Papp B, Locke F, Ladds M, Pastor-Fernández A, Gelebart P, McCormack E.  Dihydroorotate dehydrogenase inhibition acts synergistically with tyrosine kinase inhibitors to induce apoptosis of mantle cell lymphoma cells. 2022 May 15;3(3):913-918
  2. Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, Sánchez-Gómez LM, Imaz-Iglesia I, Garcia P, Demotes J, Banzi R, Porcher R; PERMIT Group. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open. 2022 May 6;12(5):e052926.
  3. Fosse V, Oldoni E, Gerardi C, Banzi R, Fratelli M, Bietrix F, Ussi A, Andreu AL, McCormack E, The Permit Group. Evaluating Translational Methods for Personalized Medicine-A Scoping Review. J Pers Med. 2022 Jul 19;12(7):1177.
  4. Kleinmanns K, Gullaksen SE, Bredholt G, Davidson B, Torkildsen CF, Grindheim S, Bjørge L, McCormack E. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies.Cancers (Basel). 2022 Jun 23;14(13):3092.
  5. Kotopoulis S, Lam C, Haugse R, Snipstad S, Murvold E, Jouleh T, Berg S, Hansen R, Popa M, McCormack E, Gilja OH, Poortinga A. Formulation and characterisation of drug-loaded antibubbles for image-guided and ultrasound-triggered drug delivery. Ultrason Sonochem. 2022 Apr;85:105986.
  6. Kotopoulis S, Popa M, Mayoral Safont M, Murvold E, Haugse R, Langer A, Dimcevski G, Lam C, Bjånes T, Gilja OH, Cormack EM. SonoVue® Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Pharmaceutics. 2022 Jan 1;14(1):98.
  7. Eikrem O, Kotopoulis S, Popa M, Mayoral Safont M, Fossan KO, Leh S, Landolt L, Babickova J, Gudbrandsen OA, Gilja OH, Riedel B, Schjøtt J, McCormack E, Marti HP. Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. 2021 Nov 29;13(12):2038.
  8. Popa M, Fosse V, Kleinmanns K, Bjørge L, McCormack E. Xenograft models of ovarian cancer for therapy evaluation. Methods Mol. Biol. 2021 Methods Mol Biol. 2022;2424:275-293.
  9. Garcia de Jalon E, de Garibay, GR,Haug BE, McCormack E. CytoCy5S™, a compound of many structures. In vitro and in vivo evaluation of four near-infrared fluorescent substrates of nitroreductase (NTR). Dyes and Pigments. 2021, 109553
  10. Zhang J, Terán G, Popa M, Madapura H, Ladds MJGW, Lianoudaki D, Grünler J, Arsenian-Henriksson M, McCormack E, Rottenberg ME, Catrina SB, Laín S, Darekar S. DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance. 2021 May 1;24(5):102494. doi: 10.1016/j.isci.2021.102494. eCollection 2021 May 21.
  11. Haaland I, Hjelle SM, Reikvam H, Sulen A, Ryningen A, McCormack E, Bruserud Ø, Gjertsen BT. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. 2021 Apr 7;10(4):833. Impact Factor (IF): 4.8
  12. Ruiz de Garibay G, García de Jalón E, Stigen E, Lund KB, Popa M, Davidson B, Safont MM, Rygh CB, Espedal H, Barrett TM, Haug BE, McCormack E. Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. Theranostics. 2021 Apr 7;11(12):6044-6057. IF: 8.6
  13. Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, Torkzaban M, Wallace K, Eisenbrey JR, Brody JR, McCormack E, Forsberg F. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther. 2021 Mar 4;22(3):204-215. IF: 3.8
  1. Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E. Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. Br J Haematol. 2021Apr;193(2):415-419. IF: 5.5
  2. Anandan S, Thomsen LCV, Gullaksen SE, Abdelaal T, Kleinmanns K, Skavland J, Bredholt G, Gjertsen BT, McCormack E, Bjørge L. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers (Basel). 2021 Feb 11;13(4):755. IF: 6.1
  3. Kleinmanns K, Fosse V, Bjørge L, McCormack E. The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. J Pers Med. 2020 Nov 27;10(4):255. IF: 3.7
  4. Haugse R, Langer A, Murvold ET, Costea DE, Gjertsen BT, Gilja OH, Kotopoulis S, Ruiz de Garibay G, McCormack E. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Pharmaceutics. 2020 Nov 6;12(11):1058. IF: 4.8
  5. Kleinmanns K, Bischof K, Anandan S, Popa M, Akslen LA, Fosse V, Karlsen I, Gjertsen BT, Bjørge L, McCormack E. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine (2020) May 23;56:102783.IF: 5.7
  6. Kleinmanns K, Fosse V, Davidson B, Garcia de Jalon E, Tenstad O, Bjørge L, McCormack E. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine (2020) May 23;56:102782 IF: 5.7
  7. Aasebø E, Berven FS, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M, Døskeland SO, McCormack E, Batth TS, Olsen JV, Bruserud Ø, Selheim F, Hernandez-Valladares M. Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. Cancers (Basel). 2020 Mar 17;12(3). IF: 6.1
  8. Bjånes T, Kotopoulis S, Murvold ET, Kamčeva T, Gjertsen BT, Gilja OH, Schjøtt J, Riedel B*, McCormack E*. Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics. 2020 Feb 7;12(2). pii: E141. IF: 4.8
  9. Fonnes T, Strand E, Fasmer KE, Berg HF, Espedal H, Sortland K, Stefansson I, Bjørge L, Haldorsen IS, Krakstad C, McCormack E. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers (Basel). 2020 Feb 6;12(2). pii: E370. IF: 6.1
  10. Lazarian G, Friedrich C, Quinquenel A, Tran J, Ouriemmi S, Dondi E, Martin A, Mihoub I, Chiron D, Bellanger C, Fleury C, Gélébart P, McCormack E, Ledoux D, Thieblemont C, Marzec J, Gribben JG, Cymbalista F, Varin-Blank N, Gardano L, Baran-Marszak F. Stabilization of β-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma. Oncogene. 2020 Feb 7. doi: 10.1038/s41388-020-1183-x. [Epub ahead of print] IF: 7.97
  11. Omsland M, Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Tyrosine kinase inhibitors and interferon-α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020 Jan 16. doi: 10.1096/fj.201802061RR. [Epub ahead of print] IF: 4.97
  12. Bjånes TK, Jordheim LP, Schjøtt J, Kamceva T, Cros-Perrial E, Langer A, de Garibay GR, Kotopoulis S, Riedel B*, McCormack E*. Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines. Drug Metab Dispos. 2019 Dec 23. pii: dmd.119.089334. doi: 10.1124/dmd.119.089334. [Epub ahead of print] IF: 3.3
  13. Haugse R, Langer A, Gullaksen SE, Sundøy SM, Gjertsen BT, Kotopoulis S, McCormack E. Intracellular Signaling in Key Pathways Is Induced by Treatment with Ultrasound and Microbubbles in a Leukemia Cell Line, but Not in Healthy Peripheral Blood Mononuclear Cells. Pharmaceutics. 2019 Jul 6;11(7). IF: 4.8
  14. Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. IF: 3.7
  15. Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma. Cells. 2019 Feb 21;8(2). IF: 4.8
  16. Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 2018 Jun 25;18(1):684. IF: 3.2
  17. Zhang B, Durán PA, Piechaczyk L, Fløisand Y, Safont MMS, Karlsen IT, Fandalyuk Z, Tadele D, Mierlo PV, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica. 2018 May 10. pii: haematol.2018.189399. doi: 10.3324/haematol.2018.189399. [Epub ahead of print] PubMed PMID: 29748445. IF: 7.70
  18. Ladds MJGW, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, Bhatia R, Laín S. Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. PLoS One. 2018 Apr 23;13(4):e0195956. IF: 2.81
  19. de Garibay GR, Mateo F, Stradella A, Valdés-Mas R, Palomero L, Serra-Musach J, Puente DA, Díaz-Navarro A, Vargas-Parra G, Tornero E, Morilla I, Farré L, Martinez-Iniesta M, Herranz C, McCormack E, Vidal A, Petit A, Soler T, Lázaro C, Puente XS, Villanueva A, Pujana MA. Tumor xenograft modeling identifies TCF4/ITF2 loss associated with breast cancer chemoresistance. Dis Model Mech. 2018 Apr 13. pii: dmm.032292. doi: 10.1242/dmm.032292. [Epub ahead of print] IF: 4.69
  20. Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D’Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2018 Mar 16;9(1):1107. 5-Year Impact Factor (IF): 13.09
  21. Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M,Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. 2017 Aug 10;130(6):789-802. IF: 11.85
  22. Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sørnes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016 Dec 1;7(12):e2497. IF: 5.38
  1. Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvåle S, Sontum P, Gjertsen BT, Gilja OH, McCormack E. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. J Control Release. 2016 Nov 18; 245:70-80. doi: 10.1016/j.jconrel.2016.11.019. [Epub ahead of print] 5 year Impact Factor: 8.41
  2. Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016 Oct 12. pii: S0168-3659(16)30949-X. doi: 10.1016/j.jconrel.2016.10.007. PubMed PMID: 27744037. 5 year IF: 8.41 

– This article was highlighted with commentary J Control Release: Park K. Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer. J Control Release. 2016 Dec 10;243:381

  1. Bojan A, Berindan-Neagoe I, Ciurea S, Dima D, Fuji S, Ghiaur G, Grewal R, McCormack E, Tanase A, Trifa A, Tomuleasa C. Proceedings from the 1st Insights in Hematology Symposium, Cluj-Napoca, Romania March 11-12, 2016. Rom J Intern Med. 2016 Sep 1;54(3):157-160.
  2. Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.PLoS One. 2016 Jun 28;11(6):e0158208. IF: 3.23
  3. Suliman S, Mustafa K, Krueger A, Steinmüller-Nethl D, Finne-Wistrand A, Osdal T, Hamza AO, Sun Y, Parajuli H, Waag T, Nicke J, Johannessen AC, McCormack E, Costea DE. Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes. Biomaterials. 2016 Apr 6. doi:10.1016/j.biomaterials.2016.04.002 [Epub ahead of print] 5 year IF: 9.31
  4. Mamaeva V, Niemi R, Beck M, Özliseli E, Desai D, Landor S, Gronroos T, Kronqvist P, Pettersen IK, McCormack E, Rosenholm JM, Linden M, Sahlgren C. Inhibiting Notch activity in breast cancer stem cells by glucose functionalized nanoparticles carrying γ- secretase inhibitors. Mol Ther. 2016 Feb 26. doi: 10.1038/mt.2016.42. [Epub ahead of print] IF: 6.83
  5. Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget. 2016 Jan 23. doi: 10.18632/oncotarget.6991. [Epub ahead of print] IF: 6.38
  6. Gelebart P, Popa M, McCormack E. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies. Curr Pharm Biotechnol. 2016;17(1):42-51. IF: 2.51
  7. Suliman S, Parajuli H, Sun Y, Johannessen AC, Finne-Wistrand A, McCormack E, Mustafa K, Costea DE. Establishment of a bioluminescence model for microenvironmentally induced oral carcinogenesis with implications for screening bioengineered scaffolds. Head Neck. 2015 Aug 14. doi: 10.1002/hed.24187. [Epub ahead of print] IF: 2.64
  8. Haldorsen IS, Popa M, Fonnes T, Brekke N, Kopperud R, Visser NC, Rygh CB, Pavlin T, Salvesen HB, McCormack E, Krakstad C. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS One. 2015 Aug 7;10(8):e0135220.        IF: 3.23
  9. Vorobyeva AG, Stanton M, Godinat A, Lund KB, Karateev GG, Francis KP, Allen E, Gelovani JG, McCormack E, Tangney M, Dubikovskaya EA. Development of a Bioluminescent Nitroreductase Probe for Preclinical Imaging. PLoS One. 2015 Jun 25;10(6):e0131037. IF: 3.23
  10. Hampson P, Wang K, Ersvær E, McCormack E, Schüler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience. 2014 Aug 6;1(8):529-39.
  11. Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud O, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E*, Bhatia R*. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014 Oct 2;15(4):431-46. *Joint correspondence        IF: 25.56

– This article was highlighted with commentary in Cell Stem Cell: Zeisig BB, So CW. A knockout Combo: eradicating AML Stem Cells with TKI plus SIRT1 inhibition. Cell Stem Cell. 2014 Oct 2;15(4):395-7

  1. Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014 May 21;13:116.            IF: 4.26
  2. Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One. 2014 Mar 4;9(3):e89527. IF: 3.23
  3. Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget. 2013 Sep;4(9):1527-46 IF: 6.38
  4. Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, Ke XS. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res. 2013 Dec 1;73(23):7090-100. IF: 9.33
  5. Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, Gilja OH, Postema M, Gjertsen BT, McCormack E. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Mol Imaging Biol. 2014 Feb;16(1):53-62. IF: 2.47
  6. Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT. In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme. Mol Imaging. 2013 May;12(3):161-72. IF: 1.96
  7. Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis. 2013 Feb 28;4:e516. IF: 5.38
  8. Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines. PLoS One. 2013;8(2):e56276. IF: 3.23
  9. Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer. 2013 Aug 1;133(3):544-55. IF: 5.09
  10. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2013 Apr;62(4):773-85. IF: 3.94
  • Figures from this article made the front cover of the Journals April edition 2013
  1. McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121(7):e34-42. IF: 11.84
  2. McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens JB, Haug BE, Cooper ME, Gjertsen BT. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013 Feb 15;73(4):1276-86. IF: 9.33
  3. Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One. 2012;7(11):e48992 IF: 3.23
  4. Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, Iwamoto Y, Wang F, Shen K, Hatfield K, Enger M, Shafiee S, McCormack E, Ebert BL, Weissleder R, Yarmush ML, Parekkadan B. Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19638-43. IF: 9.67

– This article was highlighted with commentary in Nature Methods: de Souza N.Stem cells: Blood matters. 2013 Jan;10(1):9.

  1. Hjelle SM, Sulen A, Øye OK, Jørgensen K, McCormack E, Hollund BE, Gjertsen BT. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. J Proteomics. 2012 Dec 5;76 Spec No.:69-78. IF: 3.81
  2. Karlsen TV, McCormack E, Mujic M, Tenstad O, Wiig H. Minimally invasive quantification of lymph flow in mice and rats by imaging depot clearance of near-infrared albumin. Am J Physiol Heart Circ Physiol. 2012 Jan;302(2):H391-401 IF: 3.84
  3. McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012 May;26(5):910-7. IF: 12.10

POPULAR SCIENTIFIC CONTRIBUTIONS

  1. Holthe, K. (2016, April 4). Denne musa får menneskekreft for at du skal få bedre behandling. Retrieved from http://www.tv2.no/a/8141256/
  2. McCormack, E. (2014, October 13). Egne stamceller kan gi din helt unike kreftmedisin. Retrieved from http://www.aftenposten.no/viten/Egne-stamceller-kan-gi-din-helt-unike-kreftmedisin-7742247.html
  3. Hågøy, T. (2013, April 15). Kan revolusjonere kreftbehandlingen. Dagens Medisin. Retrieved from http://www.dagensmedisin.no/artikler/2013/04/15/kan-revolusjonere-kreftbehandlingen/
  1. Bakke, K. A. (2011, December 16). Nye muligheter for kreftprotein. Dagens Medisin. Retrieved from http://www.dagensmedisin.no/artikler/2011/12/16/nye-muligheter-for-kreftprotein/

H-index (ResearcherID: D-2922-2012): 30
H-Index (Google scholar): 30